Companies: 10,795·Total market cap: $144.5T
Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd

HKPDNASDAQHealthcare● Active
$0.48
$-0.01(-2.99%)
Market Cap$5270089
P/E Ratio
52W High$2.58
52W Low$0.37
Overview

Cellyan Biotechnology Co., Ltd (HKPD) · Income Statement

Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.

FMP · HKPD · as of 2026-06-08

Financial statements

Revenue · Gross Profit · Net Income
Breakdown2025-032024-032023-03
Revenue
Revenue$20.31M$16.69M$12.56M
Cost of Revenue$17.90M$13.13M$9.82M
Gross Profit$2.42M$3.56M$2.74M
Gross Margin %(computed)11.89%21.32%21.81%
Operating Expenses
R&D Expenses$0.00M$0.00M$0.00M
G&A Expenses$0.00M$0.00M$0.00M
Total Operating Expenses$2.28M$1.95M$1.70M
Operating Income$0.13M$1.61M$1.04M
Operating Margin %(computed)0.65%9.64%8.31%
Interest Income$0.00M$0.00M$0.00M
Interest Expense$0.10M$0.08M$0.02M
Income Before Tax$0.04M$1.53M$1.02M
Income Tax Expense$0.06M$0.20M$0.02M
Net Income($0.03M)$1.33M$1.00M
Net Margin %(computed)-0.13%7.97%7.95%
Per Share & EBITDA
EPS (Basic)$-0.00$0.18$0.09
Wtd Avg Shares9.02M7.37M11.00M
EBITDA$1.21M$2.53M$1.76M
EBITDA Margin %(computed)5.94%15.19%14.01%

Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M

Explore more Cellyan Biotechnology Co., Ltd data

About Cellyan Biotechnology Co., Ltd (HKPD) Income Statement

Cellyan Biotechnology Co., Ltd (HKPD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HKPD reported revenue of $0.02B, gross profit of $0.00B (gross margin 11.89%), and net income of ($0.00B) — a net profit margin of -0.13%.

Frequently asked questions

HKPD · 4 questions

Cellyan Biotechnology Co., Ltd (HKPD) reported revenue of $0.02B for 2025, up 21.7% year-over-year.

HKPD revenueHKPD salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08